JMP Securities downgraded Sana Biotechnology (SANA) to Market Perform from Outperform without a price target after the company announced a portfolio reprioritization. The firm cites uncertainty associated with the company’s various data readouts for the downgrade. It now sees Sana shares as fairly valued.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA: